- AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war
- Sanofi steps off the sidelines to ink 3 ADC deal with Seagen, reigniting long-held interest in the modality
- White House: Providers won't get reimbursed for uninsured COVID-19 care unless Congress acts
- Illumina launches cancer profiling diagnostic in Europe
- 'Biotech sisterhood': 25 female CEOs find new ways to 'sponsor' the next generation at Arizona retreat
- Biogen piles on more long-term Aduhelm data, linking biomarker to Alzheimer’s clinical benefit
- HIMSS 2022: Retail, primary care disruptors are hungry for partnerships with traditional providers
- BioNTech, CureVac part of $3.14B deal to bolster German vaccine capacity through 2029: report
- FDA's gene editing guidance is 'par for the course' but still important, analysts say
- Verily adds AI to Lumea’s digital pathology platform for prostate cancer
- HIMSS 2022: Microsoft rolls out Azure Health Data Services to unify clinical, imaging and medical device data
- Lilly and Boehringer's Jardiance, trailing AZ's Farxiga in chronic kidney disease, posts efficacy win
- Shionogi’s COVID-19 antiviral heads to phase 3 backed by NIH after receiving FDA go-ahead
- J&J's DePuy Synthes found guilty of infringing orthopedic device patent in $20M verdict
Featured Story | By Angus Liu,Eric Sagonowsky,Fraiser Kansteiner Since the invasion of Ukraine, hundreds of companies have announced pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are among the latest to join the growing list. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Sanofi is stepping up its long-held interest in antibody-drug conjugates (ADC). Having first teamed up with Immunogen almost 20 years ago, Sanofi has now joined forces with Seagen to jointly fund and develop three anti-cancer ADCs. read more By Robert King Starting next month, providers won't be able to get reimbursed for testing, vaccinating or treating uninsured COVID-19 patients unless Congress passes new funding, the White House warns. read more By Conor Hale Built off of its previous tumor biopsy assays reserved for use by research scientists, the new TruSight Oncology Comprehensive test kit examines multiple cancer genes and biomarkers to help direct European patients to targeted therapies. read more By Kyle LaHucik Two dozen female CEOs from across the biotech industry came together for a first-of-its-kind retreat this past weekend to network, bounce ideas off one another and form the basis for annual and regional events meant to support women in the C-suite. read more By Angus Liu Despite a disastrous commercial rollout, Biogen is still producing longer-term data for beleaguered Alzheimer’s disease therapy Aduhelm. The latest data showed that the drug continued to lower the levels of amyloid beta plaques and produced a sign of cognitive benefit, the company said. read more By Dave Muoio Executives from Best Buy, One Medical and CVS Health say there's enough healthcare demand to go around and that all organizations can benefit from collaborations on new care models. read more By Fraiser Kansteiner Germany will pay upward of €2.86 billion ($3.14 billion) to lock up local vaccine production capacity through 2029, Reuters reports, citing the country’s economy ministry. On Wednesday, the German government approved plans to sign contracts with mRNA specialists BioNTech and CureVac-GSK, plus contract manufacturers Wacker and CordernPharma, Celonic, and IDT. read more By Annalee Armstrong “Par for the course.” “Benign.” “Not surprising.” These are some of the creative ways analysts described the FDA’s new guidance on gene editing for biotechs, but they are at least happy to see the FDA take some leadership and provide guidance to industry. read more By Andrea Park Startups like Ibex, Paige and PathAI have racked up a handful of regulatory approvals and hundreds of millions in funding for their respective AI-powered biopsy-reading technologies—and now, Verily is looking for a piece of the digital pathology pie. read more By Heather Landi Microsoft is stepping up its healthcare cloud services with a new platform that brings together diverse data sets, like clinical, imaging and streaming data from medical devices, in the cloud. read more By Fraiser Kansteiner Following an interim assessment, the independent data monitoring committee in charge of Lilly and BI’s phase 3 Empa-Kidney study in chronic kidney disease (CKD) have recommended the trial stop early. At the trial’s midpoint, Jardiance met the mark for positive efficacy, the partners said. read more By Max Bayer Shionogi's COVID-19 treatment, backed by the National Institutes of Health, is moving on to phase 3 after the FDA finalized the study design, a positive step after several clinical pauses and discontinuations have marred pandemic research funded by the NIH in March. read more By Andrea Park Gary Lynn Rasmussen, M.D., accused DePuy of having used two of his patented inventions “without his permission or compensation.” His mechanisms were allegedly integrated into DePuy’s Attune system for knee replacement procedures. read more |
|
